Barclays PLC bought a new stake in Clover Health Investments, Corp. (NASDAQ:CLOV – Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 105,766 shares of the company’s stock, valued at approximately $298,000.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Concurrent Investment Advisors LLC purchased a new stake in shares of Clover Health Investments in the 3rd quarter valued at $28,000. Sigma Planning Corp purchased a new stake in Clover Health Investments during the third quarter worth about $29,000. Parallax Volatility Advisers L.P. acquired a new stake in shares of Clover Health Investments during the third quarter worth about $38,000. Vanguard Personalized Indexing Management LLC boosted its stake in shares of Clover Health Investments by 54.4% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 34,372 shares of the company’s stock valued at $42,000 after purchasing an additional 12,104 shares during the period. Finally, Realta Investment Advisors acquired a new position in shares of Clover Health Investments in the third quarter valued at approximately $44,000. Hedge funds and other institutional investors own 19.77% of the company’s stock.
Analysts Set New Price Targets
CLOV has been the topic of a number of research reports. Craig Hallum initiated coverage on shares of Clover Health Investments in a report on Tuesday, December 17th. They set a “buy” rating and a $6.00 target price on the stock. UBS Group assumed coverage on Clover Health Investments in a report on Monday, October 7th. They set a “neutral” rating and a $4.00 price target on the stock.
Clover Health Investments Stock Up 0.2 %
NASDAQ CLOV opened at $4.08 on Tuesday. Clover Health Investments, Corp. has a 52 week low of $0.61 and a 52 week high of $4.71. The firm has a 50 day moving average of $3.36 and a two-hundred day moving average of $3.02. The stock has a market capitalization of $2.04 billion, a PE ratio of -20.40 and a beta of 1.95.
Clover Health Investments (NASDAQ:CLOV – Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. The firm had revenue of $330.99 million during the quarter, compared to the consensus estimate of $347.60 million. Clover Health Investments had a negative net margin of 5.92% and a negative return on equity of 25.46%. During the same quarter in the previous year, the firm posted ($0.09) earnings per share. On average, equities research analysts expect that Clover Health Investments, Corp. will post -0.12 earnings per share for the current fiscal year.
About Clover Health Investments
Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.
Further Reading
- Five stocks we like better than Clover Health Investments
- Russell 2000 Index, How Investors Use it For Profitable Trading
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- What Is WallStreetBets and What Stocks Are They Targeting?
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- Where Do I Find 52-Week Highs and Lows?
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Clover Health Investments Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clover Health Investments and related companies with MarketBeat.com's FREE daily email newsletter.